Wegovy CVOT Data Could Pave The Way For Broad Reimbursement, CEO Says
Novo Nordisk CEO Lars Jørgensen discussed the supply and market access position of its rising obesity drug, Wegovy, during the CNBC Health Returns conference.
You may also be interested in...
Wegovy Demand Busts Through Novo Nordisk’s Expanded Capacity
Novo Nordisk said it would temporarily reduce production of the lower starting dose of Wegovy even as a second contract manufacturer has come online in April.
Novo Preempts Earnings Reveal With Preview Of Wegovy-Driven Growth
Novo Nordisk said sales increased 25% in the first quarter, driven by US demand for GLP-1 agonist Wegovy for obesity, and increased its 2023 sales growth guidance from a range of 13%-19% to 24%-30%.
Lilly And Novo Nordisk Shape Up For Obesity Treatment Battle Of The Heavyweights
Eli Lilly’s Mounjaro looks set to gain US approval for obesity this year and upcoming Phase III data could help it eclipse the huge success of Novo Nordisk’s Wegovy.